BNP Paribas Financial Markets
ARTV

BNP Paribas Financial Markets’s Artiva Biotherapeutics ARTV Stock Holding History

BNP Paribas Financial Markets’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.49K Hold
542
– – ﹤0.01% 5361
2025
Q4 		$2.33K Sell
542
-118,005
-100% -$446K ﹤0.01% 5332
2025
Q3 		$340K Buy
118,547
+117,733
+14,464% +$315K ﹤0.01% 3756
2025
Q2 		$1.23K Sell
814
-12,416
-94% -$26.1K ﹤0.01% 5119
2025
Q1 		$39.7K Buy
13,230
+3,351
+34% +$18.1K ﹤0.01% 4364
2024
Q4 		$99.6K Buy
9,879
+7,151
+262% +$85.9K ﹤0.01% 4165
2024
Q3 		$42.1K Buy
+2,728
New +$31.6K ﹤0.01% 3650

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

BNP Paribas Financial Markets's ARTV Position: Q1 2026 in Review

BNP Paribas Financial Markets held its Artiva Biotherapeutics (ARTV) position steady in Q1 2026 at 542 shares worth $3.49K. The position accounts for ﹤0.01% of the portfolio, ranked #5361.

BNP Paribas Financial Markets first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $340K in Q3 2025. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • BNP Paribas Financial Markets held 542 shares of Artiva Biotherapeutics worth $3.49K as of Q1 2026.
  • BNP Paribas Financial Markets left its Artiva Biotherapeutics share count unchanged in Q1 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5361 holding.
  • BNP Paribas Financial Markets first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Artiva Biotherapeutics position peaked at $340K in Q3 2025.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.